143 related articles for article (PubMed ID: 20887639)
1. Targeting breast cancer stem cells: fishing season open!
Ginestier C; Charafe-Jauffret E; Birnbaum D
Breast Cancer Res; 2010; 12(5):312. PubMed ID: 20887639
[TBL] [Abstract][Full Text] [Related]
2. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of melatonin on hypoxia-induced vasculogenic mimicry via suppressing epithelial-mesenchymal transition (EMT) in breast cancer stem cells.
Maroufi NF; Amiri M; Dizaji BF; Vahedian V; Akbarzadeh M; Roshanravan N; Haiaty S; Nouri M; Rashidi MR
Eur J Pharmacol; 2020 Aug; 881():173282. PubMed ID: 32580038
[TBL] [Abstract][Full Text] [Related]
4. Notch Signaling in Breast Cancer: A Role in Drug Resistance.
BeLow M; Osipo C
Cells; 2020 Sep; 9(10):. PubMed ID: 33003540
[TBL] [Abstract][Full Text] [Related]
5. PGE
Lin MC; Chen SY; He PL; Herschman H; Li HJ
Int J Cancer; 2018 Sep; 143(6):1440-1455. PubMed ID: 29658109
[TBL] [Abstract][Full Text] [Related]
6. B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells.
Zhou H; Yu C; Kong L; Xu X; Yan J; Li Y; An T; Gong L; Gong Y; Zhu H; Zhang H; Yang X; Li Y
Oncogene; 2019 May; 38(18):3371-3386. PubMed ID: 30635656
[TBL] [Abstract][Full Text] [Related]
7. Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance.
Palomeras S; Ruiz-Martínez S; Puig T
Molecules; 2018 Aug; 23(9):. PubMed ID: 30200262
[TBL] [Abstract][Full Text] [Related]
8. Targeting the perpetrator: breast cancer stem cell therapeutics.
Pal A; Valdez KE; Carletti MZ; Behbod F
Curr Drug Targets; 2010 Sep; 11(9):1147-56. PubMed ID: 20545606
[TBL] [Abstract][Full Text] [Related]
9. Stem cell-related markers in primary breast cancers and associated metastatic lesions.
Guler G; Balci S; Costinean S; Ussakli CH; Irkkan C; Suren D; Sari E; Altundag K; Ozisik Y; Jones S; Bacher J; Shapiro CL; Huebner K
Mod Pathol; 2012 Jul; 25(7):949-55. PubMed ID: 22388757
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
[TBL] [Abstract][Full Text] [Related]
11. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.
Martin-Castillo B; Lopez-Bonet E; Cuyàs E; Viñas G; Pernas S; Dorca J; Menendez JA
Oncotarget; 2015 Oct; 6(32):32317-38. PubMed ID: 26474458
[TBL] [Abstract][Full Text] [Related]
12. Reduction of the putative CD44+CD24- breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047.
Cirenajwis H; Smiljanic S; Honeth G; Hegardt C; Marton LJ; Oredsson SM
Anticancer Drugs; 2010 Nov; 21(10):897-906. PubMed ID: 20838207
[TBL] [Abstract][Full Text] [Related]
13. Machilin D, a Lignin Derived from Saururus chinensis, Suppresses Breast Cancer Stem Cells and Inhibits NF-κB Signaling.
Zhen X; Choi HS; Kim JH; Kim SL; Liu R; Yun BS; Lee DS
Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32033472
[TBL] [Abstract][Full Text] [Related]
14. PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis.
Karicheva O; Rodriguez-Vargas JM; Wadier N; Martin-Hernandez K; Vauchelles R; Magroun N; Tissier A; Schreiber V; Dantzer F
Oncotarget; 2016 Sep; 7(39):64109-64123. PubMed ID: 27579892
[TBL] [Abstract][Full Text] [Related]
15. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status.
Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Del Barco S; Martin-Castillo B; Menendez JA
Cell Cycle; 2010 Sep; 9(18):3807-14. PubMed ID: 20890129
[TBL] [Abstract][Full Text] [Related]
16. Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer.
Deng J; Wang L; Chen H; Hao J; Ni J; Chang L; Duan W; Graham P; Li Y
Oncotarget; 2016 Aug; 7(34):55771-55788. PubMed ID: 27304054
[TBL] [Abstract][Full Text] [Related]
17. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy.
Fillmore CM; Kuperwasser C
Breast Cancer Res; 2008; 10(2):R25. PubMed ID: 18366788
[TBL] [Abstract][Full Text] [Related]
18. Gene set enrichment analysis provides insight into novel signalling pathways in breast cancer stem cells.
Murohashi M; Hinohara K; Kuroda M; Isagawa T; Tsuji S; Kobayashi S; Umezawa K; Tojo A; Aburatani H; Gotoh N
Br J Cancer; 2010 Jan; 102(1):206-12. PubMed ID: 19997106
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer stem cell population in different molecular subtypes of breast cancer.
Gupta P; Singh V; Kumar S; Das A; Singh G; Bal A
Breast Dis; 2022; 41(1):199-203. PubMed ID: 35068436
[TBL] [Abstract][Full Text] [Related]
20. Stem cell programs in cancer initiation, progression, and therapy resistance.
Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
